Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.

The influence of graft composition on clinical outcomes after reduced-intensity conditioning is not well-characterized. In this report we prospectively enumerated CD34+, CD3+, CD4+, and CD8+ cell doses in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) allografts in 63 patients who received transplants following non-myeloablative conditioning with total body irradiation 200 cGy plus fludarabine as treatment for malignant diseases. Donors were HLA-identical siblings (n = 38) or HLA-matched unrelated individuals (n = 25). By univariate analyses G-PBMC CD8+ T-cell dose in at least the 50th percentile favorably correlated with full donor blood T-cell chimerism (P = .03), freedom from progression (P = .001), and overall survival (P = .01). No G-PBMC cell dose influenced grade II to IV acute or extensive chronic graft-versus-host disease. In multivariate analysis only G-PBMC CD8+ T-cell dose (P = .003; RR = 0.2, 95% CI = 0.1-0.6) was associated with improved freedom from progression. Infusion of low G-PBMC CD8+ T-cell dose for reduced-intensity allografting may adversely affect T-cell engraftment and survival outcome.

[1]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[2]  S. Heimfeld,et al.  Allogeneic peripheral blood stem cell graft composition affects early T‐cell chimaerism and later clinical outcomes after non‐myeloablative conditioning , 2005, British journal of haematology.

[3]  N. Geller,et al.  Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. , 2004, Blood.

[4]  D. Couriel,et al.  CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. , 2004, Blood.

[5]  S. Mackinnon,et al.  CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion. , 2004, Blood.

[6]  F. Appelbaum,et al.  Thomas' hematopoietic cell transplantation , 2003 .

[7]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[8]  M. Höglund,et al.  A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. , 2003, Experimental hematology.

[9]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[10]  S. Yamasaki,et al.  Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors , 2003, Bone Marrow Transplantation.

[11]  J. Miguel,et al.  Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. , 2003, Blood.

[12]  K. Klarmann,et al.  In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals. , 2003, Blood.

[13]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[14]  F. Baron,et al.  Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. , 2003, Haematologica.

[15]  W. Siegert,et al.  Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor , 2003, Bone Marrow Transplantation.

[16]  S. Heimfeld.  Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? , 2003, Leukemia.

[17]  S. Heimfeld.  HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? , 2003, Bone Marrow Transplantation.

[18]  G. Juliusson,et al.  Adjusted Conditioning for Allogeneic Transplantation in a Single Center Setting: Mixed Chimerism Heralds Relapse , 2003, Leukemia & lymphoma.

[19]  N. Schmitz,et al.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. , 2002, Blood.

[20]  C. Scheid,et al.  Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study , 2002, Annals of Hematology.

[21]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[22]  T. Klingebiel,et al.  CD34 stem cell dose and development of extensive chronic graft-versus-host disease. , 2002, Blood.

[23]  R. Hoppe,et al.  Mixed chimerism and immunosuppressive drug withdrawal after hla-mismatched kidney and hematopoietic progenitor transplantation1 , 2002, Transplantation.

[24]  F. Baron,et al.  Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. , 2002, Journal of hematotherapy & stem cell research.

[25]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[26]  P. Huie,et al.  Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor–αβ , 2001 .

[27]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[28]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[29]  I. Weissman,et al.  CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. , 1999, Immunity.

[30]  R. Storb,et al.  A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. , 1999, Blood.

[31]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[32]  J. Román,et al.  Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse , 1999, Bone Marrow Transplantation.

[33]  P. Chow,et al.  A comparative study on the efficacy of CD8-positive cells in enhancing allogeneic bone marrow engraftment: cell sorting vs microbead selection , 1998, Bone Marrow Transplantation.

[34]  A. Grañena,et al.  Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase , 1997, Bone Marrow Transplantation.

[35]  K. Kochanek,et al.  Recommended framework for presenting injury mortality data. , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[36]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[37]  S. Strober,et al.  THE ROLE OF PURIFIED CD8+ T CELLS IN GRAFT‐VERSUS‐LEUKEMIA ACTIVITY AND ENGRAFTMENT AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION , 1995, Transplantation.

[38]  Simon C Watkins,et al.  Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. , 1994, Blood.

[39]  T. Reichert,et al.  SELECTIVE DEPLETION OF CD8+ CELLS FOR PREVENTION OF GRAFT‐VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION A RANDOMIZED CONTROLLED TRIAL , 1994, Transplantation.

[40]  P. Martin,et al.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans , 1993, The Journal of experimental medicine.

[41]  D. Jewell,et al.  Lymphocyte subset reference ranges in adult Caucasians. , 1991, Clinical immunology and immunopathology.

[42]  K. Atkinson,et al.  Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. , 1987, Bone marrow transplantation.

[43]  B. Dupont,et al.  Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. , 1986, Blood.

[44]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts , 1985 .

[45]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[46]  B. Barlogie,et al.  Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. , 2003, Experimental hematology.

[47]  J. Radich,et al.  Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases , 2002, International journal of hematology.

[48]  P. Huie,et al.  Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-alphabeta. , 2001, Blood.

[49]  S. Singhal,et al.  A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? , 2000, Bone Marrow Transplantation.

[50]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. , 1985, Blood.

[51]  D.,et al.  Regression Models and Life-Tables , 2022 .